Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

R&D Outsourcing Reaches Tipping Point As More Firms Do Most Trials Overseas

Executive Summary

Five years ago, Wyeth hit a roadblock in developing the intravenous antibiotic Tygacil (tigecyline) - not enough patients were enrolling in its Phase III trial

You may also be interested in...



Clinical Trial Modernization, Outsourcing Concerns Are Focus Of FDA/Duke Effort

In an FDA-Duke University Medical Center partnership to modernize the way clinical trials are conducted, close attention will be paid to the increase of outsourcing and off-shoring clinical trials

Clinical Trial Modernization, Outsourcing Concerns Are Focus Of FDA/Duke Effort

In an FDA-Duke University Medical Center partnership to modernize the way clinical trials are conducted, close attention will be paid to the increase of outsourcing and off-shoring clinical trials

India And China Not Yet Major Sites For FDA-Regulated Trials, Parexel Finds

While India now ranks among the top 10 countries conducting FDA-regulated clinical trials, it has yet to see a major influx of trial work

Related Content

UsernamePublicRestriction

Register

PS048311

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel